Health
Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment – MD Linx
MDLinx original journal summary on Lung Cancer, Oncology from Lung Cancer
Researchers assessed efficacy of osimertinib-based combination therapies in non-small cell lung cancer (NSCLC) patients harbouring
T790M mutations who developed progressive disease following treatment with osimertinib. Participants were NSCLC patients…
Continue Reading
-
Business12 hours agoWarning! These ASX 200 shares were just downgraded
-
Business10 hours ago2 monthly payers you’ll want to own in 2025 and beyond
-
General8 hours agoFatal house fire at Lake Illawarra under police investigation
-
Business11 hours agoAfter falling more than 20% on its FY25 result, are Inghams shares a buy the dip opportunity?